A new consortium of European organisations unite to support next generation drug discovery by providing a single view across data sources, bringing the semantic web to drug discovery.
The Open PHACTS (http://www.openphacts.org) consortium, funded by the Innovative Medicines Initiative, will reduce the barriers to drug discovery by applying semantic technologies to available data resources, creating an Open Pharmacological Space.
Currently, pharmaceutical companies expend significant and duplicated efforts aligning and integrating internal information with public data sources. This process is largely incompatible with massive computational approaches and the vast majority of drug discovery sources cannot easily interoperate.
Open PHACTS (the Open Pharmacological Concepts Triple Store) will deliver a single view across available data resources, and will be freely available to users.
Scientific text, difficult to analyse by computer, will have factual assertions extracted as semantic triples, allowing for the first time the prospect of querying textual and database data together to give answers needed to identify new drug targets and pharmacological interactions. While the semantic approach has been delivered in small-scale and targeted approaches so far, its promise for multiscale data integration has remained largely unfulfilled – Open PHACTS is a major project including many of the top semantic web experts, committed to deliver on this promise.
Success of the Open PHACTS project is likely to increasingly drive researchers around the globe to capture and distribute data and information in a semantically interoperable and computer readable format. Recognising that the power of standards lies in their widespread adoption, the core information framework is built on the principles of Open Source, Open Access and Open Data.
Gerhard Ecker, academic co-ordinator says “The Open PHACTS consortium brings together an unparalleled range of expertise, and we are committed to building a sustainable data infrastructure to support drug discovery research”
Bryn Williams-Jones, project coordinator adds ”Being able to access available resources from a single system will be a huge immediate benefit to pharmaceutical companies. Building a framework that future data can flow into will reduce information management barriers even further. ”
Initial development effort is focussed on a 6 month prototype using exemplar resources and technologies to provide a proof of concept. Identification and prioritisation of research questions will also be one of the first project milestones, driven by the pharmaceutical companies involved to deliver real answers relevant to drug discovery. Experience gained will define further development approaches to bring together data and classifications from a variety of existing public resources and other sources from the consortium members. A major community engagement exercise is part of the project, to involve data providers, software developers, publishers and commercial database producers. This will work alongside a sustainability plan to support the continuation of the Open Pharmacological Space beyond the period of funding.
The Innovative Medicines Initiative (IMI) is a unique public-private partnership between the pharmaceutical industry represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union represented by the European Commission. The total budget of the project is 16,4 million Euros and it will last for three years. The EFPIA partners will be providing data, expertise and tools to the project, while the academic partners are providing development expertise and skills drawn from academic pharmacological research, publishing, data handling, and the semantic web.
List of partners:
• Pfizer Limited
• University of Vienna
• Technical University of Denmark
• University of Hamburg
• BioSolveIT GmbH
• Consorci Mar Parc de Salut de Barcelona
• Leiden University Medical Centre
• Royal Society of Chemistry
• Vrije Universiteit Amsterdam
• Spanish National Cancer Research Centre
• University of Manchester
• Maastricht University
• Academic Concept Knowledge Ltd
• University of Santiago de Compostela
• Rheinische Friedrich-Wilhelms-Universität Bonn
• AstraZeneca AB
• GlaxoSmithKline Research and Development Ltd
• Laboratorios del Dr Esteve, S.A.
• Novartis Pharma AG
• Merck Serono
• H. Lundbeck A/S
• Eli Lilly and Company Ltd